Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Conferences 2021

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Pharmaceutical intelligence for consultancies

Focus on your clients and expand your business opportunities. We’ll help you build a complete picture of the rapidly changing pharmaceutical market with our insight and expertise.

Your trusted pharma partner

With the pharma and healthcare sector facing increasing challenges, your clients rely more than ever on independent intelligence. Pharma Intelligence will help you make smart decisions and stay ahead of a fast changing market.

What we offer

As the trusted partner of the top 50 pharmaceutical companies and 10 contract research organizations, our wide range of solutions cover early phase, clinical R&D, portfolio and strategy, regulatory and commercial planning and analysis.

We cover the life sciences business from drug and device discovery and development to regulatory approval, and drug reimbursement to lifecycle management. And we give you access to past, current and future trends and analysis.

How it helps

Whether you’re working on your next business pitch, engaging on a project for an existing client or working on due diligence for a proposed merger or acquisition; our pharmaceutical intelligence helps you meet the demands of dynamic markets and changing customer needs, with:

Expert analysis of key pharma sectors
In-depth knowledge from drug discovery to market access
Global coverage including digital health, R&D, and emerging markets
Precise analysis and data
Customized reports

Our unique strengths

Understand your clients’ world

Gain a comprehensive understanding of the global pharma market with our complete coverage.

Stay on top of the details

We’ll keep you in touch with complex regulatory and pricing and reimbursement issues.

Think ahead

Respond to market events, identify opportunities and anticipate changes by tracking drug pipelines, patent expiration and commercial activities influencing the landscape.

Deliver tailored solutions

Use our data and insight to create solutions to suit your clients’ needs.

Benefit from a dedicated service

Our services come with dedicated client service and analyst support.

View more
View Less

Relevant products

HBW Insight: Health, Beauty and Wellness

The single most comprehensive consumer healthcare information source covering regulatory, legislative, legal and commercial news across the over the counter medicines, vitamins and dietary supplements, and cosmetics industries.

Key benefits:

Get a global view
Be the first to know
Go beyond the news

Generics Bulletin

A well-respected and trusted industry source for the last 15 years, Generics Bulletin from Informa Pharma Intelligence provides in-depth news and analysis on issues that matter most to businesses across the generics, biosimilars and value-added medicines industries.

Key benefits:

Ask-the-Analyst™ Service
A powerful online platform
In-depth content coverage

Pharmaprojects

Analyze drug development by therapeutic areas, mechanisms, origins, targets and more.

Key benefits:

Curated by experts
Drug R&D landscape
Historical trends

View all content

Pink Sheet

Sputnik V COVID-19 Vaccine Causing A Stir In The EU

The team behind Sputnik V has attacked what it calls “fake news and provocations” in the EU as political arguments over the vaccine claim another ministerial scalp.

View article
Scrip

Five Phase III Data Readouts To Look Out For In Q2

Phase III trials of a number of late-stage investigational therapies are expected to read out during the second quarter of 2021, according to new analysis from Informa Pharma’s product pipeline database Biomedtracker. Some of the Phase III data could be transforming for a few of the less grand players in the pharma sector and here Scrip picks out some of the highlights to look out for in the months ahead.

View article
Generics Bulletin

FDA Guides On Generic Development During COVID-19

Guidance published by the US FDA in the form of a question-and-answer document addresses questions from ANDA applicants about generic drug development during the COVID-19 pandemic.

View article
Scrip

Shifting Research Realities After COVID-19 Place Decentralized Trials Center Stage

Agreeing that decentralized trials are here to stay, experts discussed in a recent meeting ways in which the pharma research landscape is set to change. With nearly 85% of the industry at different stages of adoption, such trials have seen greater traction in the US, while stricter data privacy laws have hampered progress in Europe, ISCR’s annual conference heard.

View article
Scrip

Scrip Asia 100 Report Extract

Access Asia Pharma Intelligence expertise and hear from Pharma journalists across Asia to reveal deep regional expertise with this sample of Scrip's Asia 100 Report.

Topic Business Strategies China Company Analysis Drug Development Landscape Market Intelligence

Single report
Scrip

Dunad Makes Debut In Protein Degradation Space

Based in Cambridge UK, Dunad believes it has developed a platform which is "tuneable and highly selective" and represents a new and differentiated targeted protein degradation approach.

View article
HBW Insight

Is The Tide Turning For EU Prebiotics And Probiotics Regulation?

More EU countries than you might think allow the terms "prebiotic" and "probiotic" on food supplement labels, suggests a survey from consultancy firm Sandwalk Bioventures. HBW Insight speaks to Sandwalk's managing director, Luis Gosalbez, about a possible move towards liberalization in the region among member states, as well as a way forward for EU regulators lagging behind this localized movement.

View article
Scrip

Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast version of Five Must-Know Things, hear about new results for Lilly in Alzheimer’s, a US delay for AbbVie, progress for Zolgensma in the UK, challenges for AstraZeneca’s coronavirus vaccine, and a Scrip roundtable on industry lessons from the pandemic.

View article
Biomedtracker, Scrip

39th Annual J.P. Morgan Healthcare Conference 2021

Keep up with events as they unfold at the 39th Annual J.P. Morgan Annual Healthcare Conference on January 11-14, 2021. Pharma Intelligence and Insights journalists will bring you real time reporting, highlighting important events and key takeaways from every day of the largest and most informative healthcare investment symposium in the industry.

View analysis
Scrip

Moderna Not Immune To COVID-19 Effects On Trials

Company suspends enrolment to trials as coronavirus travel restrictions bite.

Topic Coronavirus

View article
Generics Bulletin

Pfizer Breaks With Biosimilars In China Through WuXi Bio Deal

Pfizer has announced plans to put a lid on its biosimilars programs in China, while agreeing the sale of its manufacturing site in Hangzhou.

View article
Pink Sheet

Real-World Evidence On COVID 19 Vaccines Coming Into US FDA

Peter Marks says agency is getting first RWE readouts of vaccine safety; AstraZeneca’s vaccine has no expiration date, so stockpile is not currently at risk of being thrown out, the CBER director tells a House hearing.

View article
Scrip

Pandemic Perspectives: R&D Lessons Learned From The COVID Year

The ways companies found to move forward during the challenging year also offer opportunities for industry to improve. During a roundtable discussion with Scrip, execs from Athira, Cartesian, Cyclacel, Tonix and VOZ Advisors weighed in on the adaptations they made and what changes they’ll stick with.

View article
HBW Insight

Ulta Beauty Will Have New CEO, Target Store Presence In Climb Back To 2019 Top Line

The specialty retailer, entering Target stores in the fall, is aiming for net sales of $7.2bn to $7.3bn in fiscal 2021, compared with $6.15bn in 2020 and $7.4bn in 2019. President Dave Kimbell will be taking the helm in June while CEO Mary Dillon stays on for one year as executive chair of the board.

View article
Scrip

AstraZeneca’s COVID-19 Vaccine PR Nightmare Won’t Faze Investors

Comment: While the travails around the COVID-19 vaccine continue, AstraZeneca has plenty in its pipeline to cheer investors.

View article